CureDuchenne Ventures

Summary

The fund has exact preference in a number of founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Capricor Therapeutics, 4D Molecular Therapeutics, Exonics Therapeutics Among the most successful fund investment fields, there are Medical Device, Genetics.

The top amount of exits for fund were in 2019. The high activity for fund was in 2019. The fund is generally included in less than 2 deals every year. The real fund results show that this Corporate Investor is 30 percentage points more often commits exit comparing to other companies. This CureDuchenne Ventures works on 21 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars.

The overall number of key employees were 3.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the CureDuchenne Ventures, startups are often financed by Tavistock Life Sciences, Takeda Pharmaceutical, Moore Venture Partners. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Logos Capital, Viking Global Investors. In the next rounds fund is usually obtained by The Column Group, National Institutes of Health.